FindTrial
Sign In

Semaglutide Injection

DRUG12 trials

Sponsors

Kimitsu Chuo Hospital, Kitasato University, Hangzhou Jiuyuan Gene Engineering Co. Ltd.,, Chengdu Brilliant Pharmaceutical Co., Ltd., Skye Bioscience, Inc.

Conditions

Diabetes Mellitus, Type 2Non-diabetic ObesityObesityObsesity patientsOverweightType 2 DiabetesType 2 Diabetes MellitusWeight Management

Phase 1

A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults
RecruitingNCT07465965
Shanghai World Leader Pharmaceutical Co., Ltd.Obesity, Overweight
Start: 2026-03-02End: 2026-08-30Target: 60Updated: 2026-03-12

Phase 2

Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo
Active, not recruitingNCT06577090
Skye Bioscience, Inc.Obesity
Start: 2024-08-22End: 2027-02-28Updated: 2026-01-14
A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)
Active, not recruitingNCT07073417
Hangzhou Sciwind Biosciences Co., Ltd.Obesity, Weight Management
Start: 2025-07-28End: 2027-08-23Updated: 2026-04-13

Phase 3

A Study of the Efficacy and Safety of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus
CompletedNCT05816057
Hangzhou Jiuyuan Gene Engineering Co. Ltd.,Diabetes Mellitus, Type 2
Start: 2022-07-25End: 2023-10-31Updated: 2024-01-03
Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes
Not yet recruitingNCT06339086
Chengdu Brilliant Pharmaceutical Co., Ltd.Type 2 Diabetes Mellitus
Start: 2024-04-30End: 2025-12-30Target: 478Updated: 2024-04-01
A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes
Active, not recruitingNCT06649344
Fujian Shengdi Pharmaceutical Co., Ltd.Type 2 Diabetes
Start: 2024-10-31End: 2026-09-30Updated: 2025-06-12
A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity
Active, not recruitingNCT07285902
Fujian Shengdi Pharmaceutical Co., Ltd.Obesity
Start: 2025-12-25End: 2027-03-01Updated: 2026-02-27
Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)
Not yet recruitingNCT07653477
The United Bio-Technology (Hengqin) Co., Ltd.Type 2 Diabetes
Start: 2026-07-30End: 2028-02-29Target: 956Updated: 2026-06-17

Phase 4

PEG-rhGH and Semaglutide Combination Therapy in Non-Diabetic Obese Adults
Not yet recruitingNCT06863363
Shanghai Zhongshan HospitalNon-diabetic Obesity
Target: 212Updated: 2025-03-07

Unknown Phase

Assessing patient satisfaction following treatment with Semaglutide injection for type 2 diabetes mellitus
Active, not recruitingJPRN-UMIN000053067
Kimitsu Chuo Hospitaltype 2 diabetes mellitus
Start: 2020-09-01Target: 80Updated: 2026-06-29
A study on the safety and efficacy of semaglutide in obese patients
RecruitingJPRN-UMIN000053714
Kitasato UniversityObsesity patients
Start: 2024-03-01Target: 50Updated: 2026-06-29
The Effect of Semaglutide on the Intestinal Flora in Obesity
Not yet recruitingNCT07323134
Beijing Chao Yang HospitalObesity
Start: 2026-02-01End: 2026-08-01Target: 40Updated: 2026-01-07

Related Papers

2849-LB: Efficacy and Safety of cAMP-Biased Ecnoglutide vs. Unbiased Semaglutide in Adults with Obesity: Twenty-Week Results from a Multicenter, Randomized, Open-Label, Phase 2 Study
Diabetes2026-06-05